EQUILLIUM, INC. (EQ) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 3.16M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -19.30M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $3.16M | $-19.30M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $2.63M | $-20.37M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $2.32M | $-23.63M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $2.41M | $-24.37M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $3.01M | $-20.48M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $3.40M | $-14.35M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $41.09M | $3.75M | $-8.27M | (m) | (m) | 9.13% | (m) | (m) |
| 2024-09-30 | (m) | $45.91M | $3.98M | $-6.77M | (m) | (m) | 8.66% | (m) | (m) |
| 2024-06-30 | (m) | $42.62M | $3.95M | $-9.71M | (m) | (m) | 9.26% | (m) | (m) |
| 2024-03-31 | (m) | $37.89M | $3.93M | $-13.21M | (m) | (m) | 10.37% | (m) | (m) |
| 2023-12-31 | $37.04M | $36.08M | $4.00M | $-14.52M | (m) | 102.65% | 11.08% | (m) | (m) |
| 2023-09-30 | (m) | (m) | $4.00M | $-9.28M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $4.21M | $-18.89M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $4.58M | $-28.86M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $37.55M | $15.76M | $4.84M | $-62.08M | (m) | 238.26% | 30.72% | (m) | (m) |
| 2022-09-30 | (m) | (m) | $4.94M | $-74.50M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $4.90M | $-71.13M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $4.66M | $-66.42M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $26.38M | (m) | $4.41M | $-37.79M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $25.40M | (m) | $4.09M | $-36.37M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $22.65M | (m) | $3.79M | $-33.02M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $20.56M | (m) | $4.07M | $-30.79M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $19.38M | (m) | $3.82M | $-29.55M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $18.27M | (m) | $3.58M | $-28.19M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $18.23M | (m) | $3.36M | $-28.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $18.59M | (m) | $2.59M | $-27.83M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $17.64M | (m) | $2.25M | $-26.73M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $14.71M | (m) | $1.97M | $-23.34M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $11.75M | (m) | $1.47M | $-19.24M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $8.04M | (m) | (m) | $-13.93M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $4.94M | (m) | $441.91K | $-8.62M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |